Health Check
Johnson & Johnson has $24 billion in cash with consistent free cash flow generation exceeding $18 billion annually. As one of only two companies with a AAA credit rating (the other is Microsoft), J&J has one of the strongest balance sheets in corporate America.
Revenue grew 5.2% to $88 billion, driven by strong pharmaceutical sales and the MedTech division. The Innovative Medicine segment saw particular strength from oncology and immunology drugs. This is solid, dependable growth for a company this size.
At a P/E ratio of about 16, J&J is priced below the market average of 22. For a company with this level of stability, cash flow, and dividend history, this represents reasonable value. You are paying $16 for every $1 earned.
J&J shares have been on a quiet uptrend, gaining about 7% over three months. The stock trades above its moving averages. It does not have explosive moves like tech stocks, but it consistently grinds higher — exactly what income investors want.
Analysts are generally positive on J&J fundamentals but cautious about ongoing talc litigation settlements. The pharmaceutical pipeline is strong, but generic competition for some key drugs creates uncertainty. Most rate it a hold with a positive bias.
News
You Do Not Need 30 Years of Federal Service to Build a Pension. Here Is the $495,000 Dividend Portfolio That Pays Like One
A federal employee retiring at 62 after 30 years of service with a “high-3” salary average of $90,000 would receive an estimated FERS basic pension benefit of roughly $29,700 annually, based on the standard formula: 1.1% × 30 years × $90,000. For private-sector workers without access to a defined-benefit pension, that figure provides a useful ... You Do Not Need 30 Years of Federal Service to Build a Pension. Here Is the $495,000 Dividend Portfolio That Pays Like One
Late-Stage Chronic Kidney Disease Market Analysis Report 2026-2036, Profiles of Key Players - Novartis, Merck & Co, Pfizer, Sanofi, and Johnson & Johnson
The late-stage chronic kidney disease (CKD) market is experiencing significant growth, driven by rising global prevalence of diabetes, hypertension, and aging populations. Advanced treatments like dialysis and kidney transplants are increasingly necessary as late-stage CKD progresses to end-stage renal disease (ESRD). Innovations in dialysis technologies, such as portable and home-based systems, alongside telemedicine integration, are enhancing patient care and treatment adherence. Emerging mark
CDL’s $2.29 annual dividend beats Treasury yields despite rising interest rates
Income investors holding the VictoryShares US Large Cap High Div Volatility Wtd ETF (NYSEARCA:CDL) own a fund built around one premise: large American companies with stable share prices tend to pay reliable dividends. CDL distributes cash monthly and paid $2.29 per share in 2025 against a current share price of roughly $76. With Treasury yields ... CDL’s $2.29 annual dividend beats Treasury yields despite rising interest rates
Financials
JNJ revenue from the latest annual FMP income statement.
JNJ diluted EPS from the latest annual FMP income statement.
JNJ operating cash flow from the latest annual FMP cash flow statement.
JNJ gross margin from FMP trailing-twelve-month ratios.